Faithward Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Faithward Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.72M	Buy	38,339 +9,065	+31%	+$1.58M	1.1%	23
2025 Q4	$4.98M	Buy	29,274 +1,370	+5%	+$210K	0.73%	37
2025 Q3	$3.68M	Buy	27,904 +13,475	+93%	+$1.62M	0.55%	60
2025 Q2	$1.53M	Buy	14,429 +663	+5%	+$72K	0.24%	86
2025 Q1	$1.71M	Sell	13,766 -557	-4%	-$72.7K	0.3%	80
2024 Q4	$1.76M	Buy	14,323 +460	+3%	+$54.2K	0.3%	80
2024 Q3	$1.54M	Sell	13,863 -257	-2%	-$28.2K	0.27%	90
2024 Q2	$1.51M	Buy	14,120 +261	+2%	+$28.7K	0.27%	89
2024 Q1	$1.67M	Buy	13,859 +165	+1%	+$20.2K	0.3%	77
2023 Q4	$1.67M	Buy	13,694 +2,780	+25%	+$347K	0.37%	65
2023 Q3	$1.33M	Buy	+10,914	New	+$1.45M	0.32%	67

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Faithward Advisors's JAZZ Position: Q1 2026 in Review

Faithward Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 31% in Q1 2026, buying an estimated $1.58M and bringing the position to 38,339 shares worth $7.72M. The position accounts for 1.1% of the portfolio, ranked #23.

Faithward Advisors first reported a position in JAZZ in Q3 2023 and has held it in 11 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Faithward Advisors held 38,339 shares of Jazz Pharmaceuticals worth $7.72M as of Q1 2026.
Faithward Advisors bought 9,065 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.58M.
Jazz Pharmaceuticals made up 1.1% of Faithward Advisors's portfolio in Q1 2026, its #23 holding.
Faithward Advisors first reported a position in Jazz Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Faithward Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.